GBA3
Glucosylceramidase beta 3 (gene/pseudogene)Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 49 | 47 | 0 |
| Samples | 48 | 46 | 0 |
| Peptides | 46 | 44 | 0 |
Function
GBA3 · Glucosylceramidase beta 3 (gene/pseudogene)
The protein encoded by this gene is a cytosolic enzyme that can hydrolyze several types of glycosides. The enzyme has its highest activity at neutral pH and is predominantly expressed in human liver, kidney, intestine, and spleen. This gene is a polymorphic pseudogene, with the most common allele being the functional allele that encodes the full-length protein. Some individuals contain a single nucleotide polymorphism that results in a premature stop codon in the coding region, and therefore this allele is pseudogenic due to the failure to produce a functional full-length protein. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Apr 2022].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000508166 | - | 49 | 46 |
Gene Properties
Recurrent Mutations
All 46 amino-acid changes on canonical ENST00000508166 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GBA3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GBA3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Adrenocortical Carcinoma | 1/3 33% | 0/112 0% |
| Endometrial Carcinoma | 3/42 7% | 1/612 0% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Neuroendocrine Tumour | 3/154 2% | 0/577 0% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 0/1390 0% |
| Melanoma | 6/210 3% | 0/1899 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 0/810 0% |
| Biliary Tract Carcinoma | 2/54 4% | 0/950 0% |
| B-Lymphoblastic Leukemia | 4/55 7% | 0/2640 0% |
| Small Cell Lung Carcinoma | 1/9 11% | 0/752 0% |
| Pancreatic Carcinoma | 2/89 2% | 0/1611 0% |
| Gastric Carcinoma | 2/74 3% | 0/1809 0% |
| Non-Cancerous | 1/104 1% | 0/830 0% |
| Ovarian Carcinoma | 1/109 1% | 0/998 0% |
| Colorectal Carcinoma | 2/143 1% | 1/3239 0% |
| Prostate Carcinoma | 2/13 15% | 0/2105 0% |
| Breast Carcinoma | 2/144 1% | 0/3264 0% |
| Other Solid Cancers | 1/94 1% | 0/1515 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 0/2550 0% |
Mutation Distribution
Where GBA3 is mutated · all tissues, split by cell line vs tissue
How many mutations in GBA3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 42 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 49 mutations in GBA3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|